28
PRESENTED BY THUSHARA C PHARMACY PRACTICE

Schizophrenia

Embed Size (px)

Citation preview

Page 1: Schizophrenia

PRESENTED BYTHUSHARA C

PHARMACY PRACTICE

Page 2: Schizophrenia

Schizophrenia is a chronic heterogeneous syndrome of disorganized and bizarre thoughts, delusions, hallucinations, inappropriate affect, cognitive deficits, and impaired psychosocial functioning

Page 3: Schizophrenia

• It is a psychotic disorder marked by severely impaired thinking, emotions and behaviours. Schizophrenic patients are unable to filter sensory stimuli and may have enhanced perception of sounds, colours and other features of their environment.

• Most schizophrenics, if untreated can gradually withdraw themselves from the interactions with other people and lose their ability to take care of personnel needs

Page 4: Schizophrenia

TYPES OF SCHIZOPHRENIA

CATATONICMotor symptoms are most notable. The patient may either demonstrate rigid immobility or excessive purposeless movement. The patient may be silent and withdrawn or may become loud and shout. Bizarre voluntary movements such as posturing may also occur.The patient may fluctuate between the two extremes.

DISORGANISEDThe patient tends to have disorganized speech and behavior with a fl at affect. Hallucinationsand delusions are not well formed and fragmented. The patient may also have bizarremannerisms and grimacing.

Page 5: Schizophrenia

PARANOIDThe most common type of schizophrenia. Patients are usually preoccupied with paranoid delusions or auditory hallucinations. Cognitive function is usually preserved; if thought disorder is present, it does not prevent description of delusions or hallucinations.

RESIDUALThe patient does not have acute psychosis, but some symptoms of schizophrenia remain.Largely negative symptoms are seen, such as flat affect, social withdrawal, and looseassociations. Prominent delusions or hallucinations are not present.

Page 6: Schizophrenia

UNDIFFERENTIATED The patient meets the criteria for a diagnosis of schizophrenia but does not meet the criteria for a specific type, or the patient may meet the criteria for multiple types of schizophrenia. No one type appears to be dominant.

Page 7: Schizophrenia

EPIDEMIOLOGY

Lifetime prevalence of schizophrenia ranges from 0.6% to 1.9%, with an average of approximately 1%.The worldwide prevalence of schizophrenia is remarkably similar among all cultures.Schizophrenia most commonly has its onset in late adolescence or early adulthood and rarely occurs before adolescence or after the age of 40 years. The prevalence of schizophrenia is equal in males and females.

Page 8: Schizophrenia

SYMPTOMS OF SCHIZOPHRENIA

POSITIVE SYMPTOMS

DELUSIONHALLUCINATIONCOMBATIVENESSINSOMNIA

NEGATIVE SYMPTOMSAffective flatteningAlogiaAnhedoniaAmotivationApathyAsocial behavior

DISORGANIZED SYMPTOMS

Disorganized speechThought disorderDisorganized behaviorPoor attention

Page 9: Schizophrenia

ETIOLOGY

• No one knows the exact causes of Schizophrenia, but multiple possible factors have been discovered.

• These factors include:

1. Genetics

2. Brain chemical imbalance

3. Environmental factors

4. Family history

Page 10: Schizophrenia

PATHOPHYSIOLOGY

Genetic Theory:

• A strong genetic link exists for the development of schizophrenia.

Occurs in 1% of general population, however this increases to 10% if a 1st degree relative has a history of schizophrenia.

Risk of developing schizophrenia further increases to 40% when both parents have a history of schizophrenia.

Monozygotic twins have demonstrated a 48% risk of developing schizophrenia if one twin has the disease.

Studies are going to locate specific genes to the development of schizophrenia.

Page 11: Schizophrenia

Dopamine Theory:•The dopamine hyperactivity in the brain is responsible for

psychotic symptoms present in schizophrenia. While dopamine hyperactivity is present in mesolimbic

pathway, other areas of the brain such as the prefrontal, frontal and temporal cortices have decrease activity during acute psychosis.

Other neurotransmitters thought to be involved in schizophrenia include 5-HT, glutamate. The role of glutamate is also being evaluated because one of its major functions is to regulate dopamine activity. Glutamate deficiency has been found to cause similar effects to that of dopamine hyperactivity.

Page 12: Schizophrenia

Neurodevelopmental Theory:•Schizophrenia occurs as a result of an in

uterodisturbance during pregnancy. Potential causes of this disturbance include upper respiratory infection, obstetric complication and neonatal hypoxia.

Page 13: Schizophrenia

Psychosocial Theories:• These theories propose that situation such

as stress, poor interpersonal skills, conflicting family, communication and various socio-economic influences are linked to development of schizophrenia.

Page 14: Schizophrenia

Neurotransmitter Abnormalities

• Abnormalities in the dopaminergic system– Hypodopaminergic activity in the mesocortical

system, leading to negative symptoms– Hyperdopaminergic activity in the mesolimbic

system, leading to positive symptoms

Page 15: Schizophrenia
Page 16: Schizophrenia

• The Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision, specifies the following criteria for the diagnosis of schizophrenia:

✓ Persistent dysfunction lasting longer than 6 months ✓ Two or more symptoms (present for at least 1 month),

including hallucinations, delusions, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms

✓ Significantly impaired functioning (work, interpersonal, or self-care)

DIAGNOSIS

Page 17: Schizophrenia

•Duration: Continuous signs of the disturbance persist for at least six months. This six-month period must include at least one month of symptoms (or less if successfully treated) that meet Criterion A.•Exclusion of schizoaffective disorder and mood disorder with psychotic features.•E: Substances/general medical condition exclusion: the disturbance is not due to the direct physiological effects of a substance (eg, a drug of abuse, a medication) or a general medical condition.• F: Relationship to a pervasive developmental disorder: If there is a history of autistic disorder or another pervasive development disorder, the diagnosis of schizophrenia is made only if prominent delusions or hallucinations are also present for at least a month (or less if successfully treated). 

Page 18: Schizophrenia

• Schizophrenic patients appear to have small brains with large ventricular volumes, indicating a relative deficit of neurons. Structural and functional brain imaging studies have strongly suggested that regions of the medial temporal lobe (e.g., hippocampus) have diminished numbers of neurons and also have demonstrated the inability of individuals with schizophrenia to activate the frontal cortex and successfully execute tasks that require frontal cortical function.

IMAGINGVentricular enlargement and cortical atrophy, as seen on CT scan, have

been correlated with chronic course, severe cognitive impairment, and non responsiveness to neuroleptic medications. Decreased frontal lobe activity seen on PET scan has been associated with negative symptoms.

 

Page 19: Schizophrenia
Page 20: Schizophrenia

TREATMENT

GOALS AND OBJECTIVES: There is currently no known cure for schizophrenia. Treatment options include psychotherapy as well as pharmacotherapy. The goals and objectives of treatment are as follows:A. Minimize symptoms of schizophreniaB. Improve quality of life and social/occupational functioningC. Prevent relapse and hospitalizationD. Minimize adverse effects of medicationsE. Prevent suicide attempts or self-harm

Page 21: Schizophrenia

NON-PHARMACOLOGICAL TREATMENT

• Psychotherapy• Family therapy

Page 22: Schizophrenia

PHARMACOLOGICAL TREATMENT

• Antipsychotic medications:Two generation of antipsychotic medications are available for treatment:

1. First generation or typical antipsychotics2. Second Generation or Atypical Antipsychotics:

Page 23: Schizophrenia

First generation or typical antipsychotics:ChlorpromazineTrifluperazineThioridazinePerphanazineFluphenazineHaloperidolLoxapine

Page 24: Schizophrenia

• Mechanism of Action:The antipsychotic effect of these medications is primarily mediated through the blockade of dopamine type 2 (D2 receptors).

Adverse effects: Sedation, anticholinergic effects,EPS hyperprolactemia,moderate weight gain Photosensitivity

Page 25: Schizophrenia

Second Generation or Atypical AntipsychoticsClonazapineRisperidoneOlanzapineQuetipineZiprasidone

Page 26: Schizophrenia

• Mechanism of action:Atypical antipsychotics are dopamine antagonists but also block 5-HT2A-receptors

Adverse effects: Sedation, anticholinergic effects

(Clonazapine, Olanzapine), EPS, DM, hyperprolactemia (Risperidone), hypercholestremia

Page 27: Schizophrenia
Page 28: Schizophrenia

THANK YOU……..